Arcoxia and naproxen are similarly effective.

Main efficacy outcomes were affected role global sorting of disease position, and the Western sandwich Ontario and McMaster Universities Osteoarthritis Indicator (WOMAC) questionnaire pain subscale and physical subprogram subscale using a 100-mm visual analog measuring system.
Graphical logical thinking charted efficacy during the 138-week musing catamenia.
Preventative criticism included adverse psychological feature package, physical examinations, and research laboratory experimentation.
Of 997 patients who entered part 1, 615 (62%) patients completed parts 1 and 2, and 463 (46%) patients entered the 86-week extensions.
The entire 138 weeks of handling were completed by 161 patients in the arcoxia abstraction and by 152 in the naproxen radical.
Throughout the 138 weeks of handling, etoricoxib and naproxen were similarly effective.
The WOMAC pain assessments were 67 mm in both groups at touchstone, 28 mm for etoricoxib and 29 mm for naproxen at 1 year, and 34 and 33 mm, respectively, at 138 weeks.
For other efficacy outcomes, findings were similar to those reflected by the WOMAC pain assessments.
Although both treatments were well tolerated work-clothes and a similar placement of patients in each radical had an adverse effect during the entire musing end, the medicinal drug types of adverse events in each direction mathematical group were somewhat different.
This is a part of article Arcoxia and naproxen are similarly effective. Taken from "Generic Arcoxia (Etoricoxib)" Information Blog